DIVISLABDivi's Laboratories
Pharma · API Manufacturing · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Divi's Laboratories operates in the API Manufacturing space within the Pharma sector.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on DIVISLAB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 27.8% YoY
- • Profit growth: 65.7% YoY
- • ROCE: 17.8%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +21.9%
Bull case
- • Revenue growth: 27.8% YoY
- • Profit growth: 65.7% YoY
- • ROCE: 17.8%
- • Price vs SMA200: above
Bear case
- • Valuation vs sector: P/E 93.6 vs sector 35.5
- • Dividend yield: 0.37%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Valuation vs sector: P/E 93.6 vs sector 35.5
- • Dividend yield: 0.37%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹225.89). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.